University of Rochester

Mark A Sullivan

John L Daiss

Edward M Schwarz

Stephen Dewhurst

Baek Kim

John G Frelinger

John Puskas

The present invention is directed to a monoclonal antibody that binds specifically to aglucosaminidase and inhibits in vivo growth of. Also disclosed are monoclonal antibody binding portions, recombinant or hybridoma cell lines, pharmaceutical compositions containing the monoclonal antibody or binding portions thereof, and methods of treatinginfection and osteomyelitis, and methods for introducing an orthopedic implant into a patient using the monoclonal antibody, binding portion, or pharmaceutical composition of the present invention.

Anti-glucosaminidase passive immunization forinfections

[object Object]

The present invention is directed to a monoclonal antibody that binds specifically to aglucosaminidase and inhibits in vivo growth of. Also disclosed are monoclonal antibody binding portions, recombinant or hybridoma cell lines, pharmaceutical compositions containing the monoclonal antibody or binding portions thereof, and methods of treating 5*.infection and osteomyelitis, and methods for introducing an orthopedic implant into a patient using the monoclonal antibody, binding portion, or pharmaceutical composition of the present invention.

The present invention relates to an anti-idiotypic polypeptide scaffold that includes two or more peptide sequences that mimic a discontinuous epitope of a pathogen that is recognized by or induces formation of a broadly neutralizing antibody. Using a fibronectin FNfn10 scaffold bearing two or more modified discontinuous loops, scaffolds that recognize broadly neutralizing antibodies in vitro and from patient serum have been identified. These scaffolds should induce an immune response or mobilize germline specificities to initiate their affinity maturation.

Antigenic mimics of discontinuous epitopes of pathogen recognized by broadly neutralizing antibodies

Provided herein are chimeric nucleic acid sequences encoding chimeric polypeptides. Also provided herein are chimeric polypeptides. Further provided herein are methods of treating a subject with or at risk of developing a cancer. The methods comprise selecting a subject with or at risk of developing a cancer, and administering to the subject an effective amount of the chimeric polypeptides provided herein.

Growing community of inventors

Fairport, NY, United States of America

Mark A Sullivan